MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with I

Ivacaftor

Ivacaftor 75mg tablets

No stability information

Stability notes for Ivacaftor 75mg tablets

There are no stability notes for this medicine.

Supplier

Kalydeco 75mg tablets (Vertex Pharmaceuticals (Europe) Ltd)

Ivacaftor 150mg tablets

Incompatible

Stability notes for Ivacaftor 150mg tablets

The thermoform foils and bottles contain a molecular sieve desiccant. Unsuitable.

Provenance

This compatibility recommendation is derived from Kalydeco 150mg tablets (Vertex Pharmaceuticals (Europe) Ltd).

Supplier

Kalydeco 150mg tablets (Vertex Pharmaceuticals (Europe) Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.